154 patents
Page 3 of 8
Utility
Processes for the Preparation of Roxadustat and Intermediates Thereof
27 Oct 22
Parven Kumar Luthra, Suhail Ahmad, Neval Kishor, Miteshgir Kanchangir Goswami, Alok Singh, Chandrasekhar Sinha, Syed Aziz Imam Quadri, Prashant Shankar Joshi, Sadanand Hardeo Maurya
Filed: 6 Aug 20
Utility
Sustained Release Olanzapine Formulations
13 Oct 22
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof.
Mark Alan Smith, Carine Claassen-Punt
Filed: 23 Jun 22
Utility
Solid State Forms of Risdiplam and Process for Preparation Thereof
6 Oct 22
The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.
Sanja Matecic Musanic, Dario Klaric, Mateja Kolenic
Filed: 28 Jul 20
Utility
Solid state forms of Pemafibrate
23 Aug 22
The present disclosure relates to solid state forms of Pemafibrate processes for preparation thereof and pharmaceutical compositions thereof.
Pavel Kolesa, Andrea Colombo, Ettore Marzorati
Filed: 21 Dec 18
Utility
Solid State Forms of Tafamidis and Salts Thereof
18 Aug 22
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Sanja MATECIC MUSANIC, Valentina TRAVANCIC, Dubravka PAVLICIC
Filed: 15 May 20
Utility
Solid State Forms of Relugolix
21 Jul 22
The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof.
Hana Kantor, Roman Gabriel, Pavel Kolesa, Alexandr Jegorov
Filed: 6 Apr 22
Utility
Solid State Forms of SAGE-217 and Processes for Preparation Thereof
14 Jul 22
The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217:Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof.
Polina Lapido, Ofir Shaul, Firas Masri
Filed: 14 May 20
Utility
Solid state forms of lumateperone ditosylate salt
17 May 22
Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.
Ariel Mittelman, Ido Fuchs, Sharona Shachantov, Doron Rudik, Rotem Sella-Erez
Filed: 8 Aug 17
Utility
Solid State Forms of Ripretinib
12 May 22
The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.
Sanja Matecic Musanic, Lara Jurkovic, Valentina Travancic
Filed: 11 Mar 20
Utility
Solid State Forms of N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE and of Its Mesylate Salt
5 May 22
The present disclosure relates to solid state forms of Encequidar (previously referred to as HM-30181A) base, Encequidar ((HM-30181A) mesylate, co-crystals of Encequidar (HM-30181A) mesylate, processes for preparation thereof, as well as pharmaceutical compositions including the same.
Petar BibuliƧ, Dijana Skalec Samec, Marina Marinkovic, Jasna Dogan
Filed: 14 Feb 20
Utility
Crystalline Solid Forms of Baricitinib
5 May 22
The present disclosure relates to cocrystals/salts of baricitinib, processes for preparation thereof as well as a pharmaceutical composition comprising the same.
Ivana Landeka, Dijana Skalec Samec, Lorena Kordic
Filed: 5 Feb 20
Utility
Solid State Forms of Lumateperone Ditosylate Salt
28 Apr 22
Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.
Ariel MITTELMAN, Ido FUCHS, Sharona SHACHANTOV, Doron RUDIK, Rotem SELLA-EREZ
Filed: 7 Jan 22
Utility
Solid state forms of Relugolix
19 Apr 22
The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof.
Hana Kantor, Roman Gabriel, Pavel Kolesa, Alexandr Jegorov
Filed: 14 Mar 19
Utility
Treating Refractory Migraine
31 Mar 22
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal, Ernesto Aycardi
Filed: 5 May 21
Utility
Pharmaceutical Composition for the Treatment of Parkinson's Disease
3 Mar 22
Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation.
Rudolf-Giesbert Alken, Frank Schneider
Filed: 16 Jul 21
Utility
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
24 Feb 22
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody.
Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
Filed: 16 Mar 21
Utility
Preventing, Treating, and Reducing (Persistent) Post-traumatic Headache
17 Feb 22
Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal
Filed: 5 Apr 21
Utility
Solid State Forms of Lumateperone Salts and Processes for Preparation of Lumateperone and Salts Thereof
27 Jan 22
Nikolina Janton, Helena Ceric, Sanja Matecic Musanic, Natasa Mrsic, Lidija Lerman, Tina D. Momcilovic, Ivana Sagud, Alexandr Jegorov
Filed: 27 Nov 19
Utility
Methods of Treating Inflammatory Pain
20 Jan 22
The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.
Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
Filed: 24 Feb 21
Utility
Solid State Forms of Reproxalap
13 Jan 22
The present disclosure relates to solid state forms of Reproxalap salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.
Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Rahul Kumar Reddy Putikum, Sudhanshu Saxena, Amol Bandal
Filed: 12 Dec 19